Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T〤ell Engager Antibody to Be Approved by the EMA for Minimal Residual DiseaseAcute lymphoblastic leukemiaHematopoietic stem cell transplantMinimal residual diseaseCHMPPRACEMACOMPOn November 15, 2018, the Committee for Medicinal Products for...
Julia Stevens, PharmD, BCOP:Tebentafusp is given kind of 2 different categories; one is a bite. So bispecific T cell engaging antibody or, excuse me, I should start that over again. So tebentafusp is sometimes called a bite therapy. So a bispe...
the first being antibody-drug conjugates such as belantamab mafodotin-blmf, bispecific T-cell engager (BiTE) immune-oncology therapies, and chimeric antigen receptor (CAR) modified T-cell therapy.5There are no ongoing clinical trials comparing belantamab mafodotin-blmf ...
; lessons learned from the bispecific t-cell engager (BiTE?) in acute lymphocytic leukemia (ALL). The most clinically advanced is the CD19/CD3 construct blinatumomab (Blincyto庐), which is approved in the US and EU for relapsed and refractory ... Greg,Friberg,David,... - 《Annals of ...
Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia. 2015. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia. Ann Pharmacother, 49(9):1057-1067.Buie... L Buie,JJ Pecoraro,TZ Horvat...
Another drug approved in 2023 via accelerated approval for treating relapsed or refractory multiple myeloma iselranatamab-bcmm(Dhillon2023b). Elranatamab is a bispecific B cell maturation antigen (BCMA) directed-CD3+T cell engager antibody (Rais et al.2023). Elranatamab binds CD3 on T cell ...